Status: Recruiting
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: CIML NK (cellular therapy) Interleukin-2 (IL-2)
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: Jun 16, 2026Locations: 2
Eligibility criteria
Participants must have histologically or cytologically confirmed recurrent epith... [+17]
Participants who have had anti-tumor chemotherapy or other investigational agent... [+15]